121 related articles for article (PubMed ID: 29574275)
1. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
Virani NA; Thavathiru E; McKernan P; Moore K; Benbrook DM; Harrison RG
Cancer Lett; 2018 Jul; 425():174-182. PubMed ID: 29574275
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
[TBL] [Abstract][Full Text] [Related]
3. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
4. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Guillen KP; Restuccia A; Kurkjian C; Harrison RG
Pancreas; 2015 Aug; 44(6):945-52. PubMed ID: 25899647
[TBL] [Abstract][Full Text] [Related]
5. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
[TBL] [Abstract][Full Text] [Related]
6. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
10. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
[TBL] [Abstract][Full Text] [Related]
11. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
12. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
13. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
15. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
16. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.
Etter AL; Bassi I; Germain S; Delaloye JF; Tschopp J; Sordat B; Dupuis M
Gynecol Oncol; 2007 Oct; 107(1):14-21. PubMed ID: 17604087
[TBL] [Abstract][Full Text] [Related]
17. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
18. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
20. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]